These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8402492)

  • 1. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
    J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
    Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
    J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy.
    Pisters KM; Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1993 Jan; 71(1):226-30. PubMed ID: 8416720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
    Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
    Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-dose-finding study of the antiemetic effect and associated plasma levels of MDL 72222 in patients receiving cisplatin.
    Logue J; Wilkinson P; Haegele KD; Orwin J
    Cancer Chemother Pharmacol; 1991; 27(6):472-6. PubMed ID: 2013117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
    Kris MG; Gralla RJ; Clark RA; Tyson LB
    J Clin Oncol; 1988 Apr; 6(4):659-62. PubMed ID: 2965755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
    Hesketh PJ
    Support Care Cancer; 1994 Sep; 2(5):286-92. PubMed ID: 8000724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
    J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
    Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
    Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
    Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
    J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous itasetron: establishing the effective dose range for the prophylactic control of acute emesis in cancer patients undergoing high-dose cisplatin chemotherapy.
    Patoia L; Del Favero A; Giglietti A; Malacarne P; Donati D; Indelli M; Bensi G; Palladino MA; Cigarini P; Kempe R; Voigt T
    Clin Oncol (R Coll Radiol); 1999; 11(2):99-104. PubMed ID: 10378635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen.
    Homesley HD; Hahne WF; McLees B; Heck K; Barrett RJ; Lentz SS; Woodlief L; Lovelace JV
    Am J Clin Oncol; 1993 Apr; 16(2):175-9. PubMed ID: 8452114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
    Coppes MJ; Lau R; Ingram LC; Wiernikowski JT; Grant R; Howard DR; Perrotta M; Barr R; Dempsey E; Greenberg ML; Leclerc JM
    Med Pediatr Oncol; 1999 Aug; 33(2):99-105. PubMed ID: 10398184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
    Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF
    Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.